BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 34951657)

  • 21. Maturity-onset diabetes of the young (MODY) in Brazil: Establishment of a national registry and appraisal of available genetic and clinical data.
    Giuffrida FMA; Moises RS; Weinert LS; Calliari LE; Manna TD; Dotto RP; Franco LF; Caetano LA; Teles MG; Lima RA; Alves C; Dib SA; Silveiro SP; Dias-da-Silva MR; Reis AF;
    Diabetes Res Clin Pract; 2017 Jan; 123():134-142. PubMed ID: 28012402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HNF1α defect influences post-prandial lipid regulation.
    St-Jean M; Boudreau F; Carpentier AC; Hivert MF
    PLoS One; 2017; 12(5):e0177110. PubMed ID: 28493909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low genetic confirmation rate in South Indian subjects with a clinical diagnosis of maturity-onset diabetes of the young (MODY) who underwent targeted next-generation sequencing for 13 genes.
    Sampathkumar G; Valiyaparambil PP; Kumar H; Bhavani N; Nair V; Menon U; Menon A; Abraham N; Chapla A; Thomas N
    J Endocrinol Invest; 2022 Mar; 45(3):607-615. PubMed ID: 34741762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes.
    Pal A; Farmer AJ; Dudley C; Selwood MP; Barrow BA; Klyne R; Grew JP; McCarthy MI; Gloyn AL; Owen KR
    Diabetes Care; 2010 Feb; 33(2):252-7. PubMed ID: 19933992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of the promoter regions of disease-causing genes in maturity-onset diabetes of the young patients.
    Komazec J; Ristivojevic B; Zukic B; Zdravkovic V; Karan-Djurasevic T; Pavlovic S; Ugrin M
    Mol Biol Rep; 2020 Sep; 47(9):6759-6768. PubMed ID: 32860162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening of HNF1A and HNF4A mutation and clinical phenotype analysis in a large cohort of Chinese patients with maturity-onset diabetes of the young.
    Wang X; Wang T; Yu M; Zhang H; Ping F; Zhang Q; Xu J; Feng K; Xiao X
    Acta Diabetol; 2019 Mar; 56(3):281-288. PubMed ID: 30293189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional Analyses of HNF1A-MODY Variants Refine the Interpretation of Identified Sequence Variants.
    Malikova J; Kaci A; Dusatkova P; Aukrust I; Torsvik J; Vesela K; Kankova PD; Njølstad PR; Pruhova S; Bjørkhaug L
    J Clin Endocrinol Metab; 2020 Apr; 105(4):. PubMed ID: 32017842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnosis of hepatic nuclear factor 1A monogenic diabetes mellitus (HNF1A-MODY) impacts antihyperglycemic treatment.
    Schnedl WJ; Holasek SJ; Schenk M; Enko D; Mangge H
    Wien Klin Wochenschr; 2021 Mar; 133(5-6):241-244. PubMed ID: 33245425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liver adenomatosis in patients with hepatocyte nuclear factor-1 alpha maturity onset diabetes of the young (HNF1A-MODY): Clinical, radiological and pathological characteristics in a French series.
    Haddouche A; Bellanne-Chantelot C; Rod A; Fournier L; Chiche L; Gautier JF; Timsit J; Laboureau S; Chaillous L; Valero R; Larger E; Jeandidier N; Wilhelm JM; Popelier M; Guillausseau PJ; Thivolet C; Lecomte P; Benhamou PY; Reznik Y
    J Diabetes; 2020 Jan; 12(1):48-57. PubMed ID: 31166087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The spectrum of HNF1A gene mutations in Greek patients with MODY3: relative frequency and identification of seven novel germline mutations.
    Tatsi C; Kanaka-Gantenbein C; Vazeou-Gerassimidi A; Chrysis D; Delis D; Tentolouris N; Dacou-Voutetakis C; Chrousos GP; Sertedaki A
    Pediatr Diabetes; 2013 Nov; 14(7):526-34. PubMed ID: 23517481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unsupervised Clustering of Missense Variants in HNF1A Using Multidimensional Functional Data Aids Clinical Interpretation.
    Althari S; Najmi LA; Bennett AJ; Aukrust I; Rundle JK; Colclough K; Molnes J; Kaci A; Nawaz S; van der Lugt T; Hassanali N; Mahajan A; Molven A; Ellard S; McCarthy MI; Bjørkhaug L; Njølstad PR; Gloyn AL
    Am J Hum Genet; 2020 Oct; 107(4):670-682. PubMed ID: 32910913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A-MODY cohort.
    Bacon S; Kyithar MP; Rizvi SR; Donnelly E; McCarthy A; Burke M; Colclough K; Ellard S; Byrne MM
    Diabet Med; 2016 Jul; 33(7):976-84. PubMed ID: 26479152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.
    Hohendorff J; Szopa M; Skupien J; Kapusta M; Zapala B; Platek T; Mrozinska S; Parpan T; Glodzik W; Ludwig-Galezowska A; Kiec-Wilk B; Klupa T; Malecki MT
    Endocrine; 2017 Aug; 57(2):272-279. PubMed ID: 28593615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mexican Carriers of the
    Martagón AJ; Bello-Chavolla OY; Arellano-Campos O; Almeda-Valdés P; Walford GA; Cruz-Bautista I; Gómez-Velasco DV; Mehta R; Muñoz-Hernández L; Sevilla-González M; Viveros-Ruiz TL; Ordoñez-Sánchez ML; Rodríguez-Guillen R; Florez JC; Tusié-Luna MT; Aguilar-Salinas CA;
    Diabetes Care; 2018 Aug; 41(8):1726-1731. PubMed ID: 29844095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apolipoprotein M can discriminate HNF1A-MODY from Type 1 diabetes.
    Mughal SA; Park R; Nowak N; Gloyn AL; Karpe F; Matile H; Malecki MT; McCarthy MI; Stoffel M; Owen KR
    Diabet Med; 2013 Feb; 30(2):246-50. PubMed ID: 23157689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of circulating microRNAs in HNF1A-MODY carriers.
    Bonner C; Nyhan KC; Bacon S; Kyithar MP; Schmid J; Concannon CG; Bray IM; Stallings RL; Prehn JH; Byrne MM
    Diabetologia; 2013 Aug; 56(8):1743-51. PubMed ID: 23674172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes.
    McDonald TJ; Shields BM; Lawry J; Owen KR; Gloyn AL; Ellard S; Hattersley AT
    Diabetes Care; 2011 Aug; 34(8):1860-2. PubMed ID: 21700917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum levels of pancreatic stone protein (PSP)/reg1A as an indicator of beta-cell apoptosis suggest an increased apoptosis rate in hepatocyte nuclear factor 1 alpha (HNF1A-MODY) carriers from the third decade of life onward.
    Bacon S; Kyithar MP; Schmid J; Rizvi SR; Bonner C; Graf R; Prehn JH; Byrne MM
    BMC Endocr Disord; 2012 Jul; 12():13. PubMed ID: 22808921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Co-inheritance of HNF1a and GCK mutations in a family with maturity-onset diabetes of the young (MODY): implications for genetic testing.
    López-Garrido MP; Herranz-Antolín S; Alija-Merillas MJ; Giralt P; Escribano J
    Clin Endocrinol (Oxf); 2013 Sep; 79(3):342-7. PubMed ID: 23009393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic and clinical characteristics of patients with HNF1A gene variations from the German-Austrian DPV database.
    Awa WL; Thon A; Raile K; Grulich-Henn J; Meissner T; Schober E; Holl RW;
    Eur J Endocrinol; 2011 Apr; 164(4):513-20. PubMed ID: 21224407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.